Kayne Anderson Rudnick Investment Management LLC lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 95,267 shares of the medical instruments supplier’s stock after selling 1,242 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in Becton, Dickinson and were worth $18,588,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Almanack Investment Partners LLC. purchased a new stake in shares of Becton, Dickinson and during the first quarter worth about $105,000. Parkside Financial Bank & Trust lifted its stake in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 9 shares in the last quarter. QCI Asset Management Inc. NY lifted its stake in shares of Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after acquiring an additional 60 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in shares of Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after acquiring an additional 240 shares in the last quarter. Finally, Financial Architects Inc lifted its stake in shares of Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after acquiring an additional 54 shares in the last quarter. Hedge funds and other institutional investors own 87.12% of the company’s stock.

A number of equities research analysts have weighed in on the company. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and lowered their price objective for the company from $210.00 to $180.00 in a research note on Friday, June 30th. Piper Jaffray Companies restated a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Bank of America Corporation reaffirmed a “buy” rating and issued a $225.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a research report on Monday, July 17th. Finally, BidaskClub upgraded Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Five equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $200.93.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/04/kayne-anderson-rudnick-investment-management-llc-has-18-59-million-holdings-in-becton-dickinson-and-company-bdx.html.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the sale, the insider now owns 12,861 shares in the company, valued at $2,538,890.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Insiders sold 75,904 shares of company stock valued at $15,242,688 over the last 90 days. 1.40% of the stock is currently owned by corporate insiders.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 193.73 on Wednesday. The company has a market cap of $44.09 billion, a price-to-earnings ratio of 56.10 and a beta of 1.05. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The firm’s 50-day moving average is $197.55 and its 200 day moving average is $192.30.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. During the same quarter last year, the firm earned $2.35 EPS. Becton, Dickinson and’s revenue for the quarter was down 5.1% compared to the same quarter last year. Equities analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 8th were paid a $0.73 dividend. The ex-dividend date was Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.51%. Becton, Dickinson and’s payout ratio is 83.43%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.